Topical calcineurin inhibitors labeling: putting the "box" in perspective.
Stern
Robert S
RS
D000279:Administration, Cutaneous; D065095:Calcineurin Inhibitors; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D017277:Drug Approval; D004348:Drug Labeling; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D014481:United States; D014486:United States Food and Drug Administration
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus